According to Gram Research analysis, a new 0-9 point scoring system using five simple clinical signs accurately identifies severe eczema in children 88.5% of the time. When children with moderate-to-severe eczema received dupilumab treatment, 86.52% achieved at least 50% skin improvement within 16 weeks, with 33.71% experiencing near-complete clearing. The scoring system considers early eczema onset, dry skin, specific skin patterns, low vitamin D, and elevated white blood cell counts.
Researchers studied 236 children with atopic dermatitis (a common type of eczema) to create a simple scoring system that helps doctors quickly identify which kids have the most severe cases. They found that five easy-to-check signs—including early onset, dry skin, a specific skin pattern, low vitamin D, and high white blood cell counts—can predict severity. The study also tested a new medicine called dupilumab and found it worked really well, with most children showing major improvement within 16 weeks. This research gives doctors better tools to diagnose and treat childhood eczema.
Key Statistics
A 2026 research study of 236 children with atopic dermatitis found that a new severity scoring system correctly identified severe cases 88.5% of the time in the initial validation group and 82.4% in an external validation group.
In a 2026 analysis of 236 children with moderate-to-severe eczema, dupilumab treatment achieved 50% or greater skin improvement in 86.52% of patients by week 16, with 33.71% experiencing 90% or greater improvement.
A 2026 study of 236 children identified five key predictors of severe eczema: early onset (age 2 or younger), dry skin, spiny lichen skin pattern, vitamin D insufficiency, and elevated eosinophil counts above 0.455×10⁹/L.
Among 236 children treated with dupilumab in a 2026 study, adverse events were mild and infrequent, with 65.17% achieving 75% or greater improvement in eczema severity by week 16.
The Quick Take
- What they studied: Can doctors use simple, everyday measurements to predict which children have the worst eczema? And does a new medicine called dupilumab actually help kids with severe eczema?
- Who participated: 236 children with atopic dermatitis (eczema) treated between 2023 and 2025. The researchers split them into two groups: 165 children used to create the scoring system, 71 children to test it, and 42 additional children from a different time period to make sure it worked in real life.
- Key finding: A simple 0-9 point scoring system using five common signs accurately predicted severe eczema in 88.5% of cases. When kids took dupilumab, 87% showed major improvement in their skin within 16 weeks, and 34% had nearly complete clearing.
- What it means for you: If your child has eczema, doctors now have a faster, simpler way to figure out how serious it is. If your doctor recommends dupilumab, research shows it’s likely to help significantly, though individual results vary and side effects are usually mild.
The Research Details
Researchers looked back at medical records from 236 children who had been treated for eczema between January 2023 and January 2025. They used a standard measurement called SCORAD (a scoring system doctors use to rate eczema severity) to classify how bad each child’s eczema was. They randomly split the children into two groups: a larger group (165 kids) to develop their new scoring system, and a smaller group (71 kids) to test whether it actually worked. They also tested it on 42 additional children treated at a different time to make sure the system worked in real-world situations.
The researchers used statistical methods called logistic regression to figure out which five simple signs were most important for predicting severe eczema: when the eczema started (age 2 or younger), how dry the skin was, a specific bumpy skin pattern called spiny lichen, vitamin D levels that were too low, and high counts of a type of white blood cell called eosinophils. They then created a simple point system (0-9 points total) based on these five signs.
For the dupilumab part, they tracked children with moderate-to-severe eczema who received this medicine and measured their skin improvement at weeks 4, 12, and 16 using standard eczema scoring systems. They also carefully recorded any side effects.
This research approach is important because it takes complicated medical information and turns it into something simple that any doctor can use quickly in their office. Instead of needing expensive tests or special equipment, doctors can just look at five basic signs and get a good idea of how severe a child’s eczema is. This helps doctors decide faster who needs stronger treatments like dupilumab.
This study is fairly reliable because it used a large group of children (236 total), tested the scoring system on two separate groups to make sure it worked consistently, and used standard medical measurements that other doctors recognize. The researchers were careful to record all side effects and used proper statistical methods. However, because this was a retrospective study (looking back at past records rather than following children forward in time), there’s always a chance some information wasn’t recorded perfectly. The study was done in one location, so results might be slightly different in other places or populations.
What the Results Show
The new scoring system worked very well. When tested on the first group of children, it correctly identified severe eczema 88.5% of the time. When tested on a completely different group of children treated later, it still worked well, correctly identifying severe cases 82.4% of the time. This shows the system is reliable and practical.
Dupilumab treatment produced impressive results. After 16 weeks of treatment, 86.52% of children showed at least a 50% improvement in their eczema (called EASI50). About 65% showed a 75% improvement (EASI75), and about 34% had nearly complete clearing of their eczema (EASI90). These improvements happened relatively quickly—many children started seeing benefits by week 4.
The five signs that best predicted severe eczema were: eczema starting at age 2 or younger, very dry skin (xerosis), a bumpy skin pattern called spiny lichen, low vitamin D levels, and high eosinophil counts (a type of white blood cell). Each of these signs added points to the severity score, with a maximum of 9 points total.
Side effects from dupilumab were generally mild and uncommon. Most children tolerated the medicine well, which is important because it means doctors can confidently recommend it to young patients. The study also found that the scoring system worked well at predicting which children would respond best to treatment, suggesting it could help doctors decide who should receive dupilumab.
Previous ways of measuring eczema severity in children often required doctors to spend a lot of time examining the skin or doing blood tests. This new system is simpler and faster while being just as accurate. Dupilumab has been studied in adults with eczema before, and this research confirms it works similarly well in children, which is important because children’s skin and immune systems are different from adults'.
This study looked back at past medical records rather than following children forward in time, which means some information might be missing or recorded differently. All the children came from one medical center, so results might be slightly different in other places or in children from different backgrounds. The study didn’t compare dupilumab to other eczema treatments, so we don’t know if it’s better or worse than alternatives. The follow-up period was only 16 weeks, so we don’t know how well the medicine works over longer periods.
The Bottom Line
If your child has eczema, ask your doctor to use this new scoring system to assess severity—it’s simple, fast, and accurate (high confidence). If your doctor diagnoses moderate-to-severe eczema and recommends dupilumab, research shows it’s likely to help significantly, with most children seeing major improvement within 4-16 weeks (high confidence). Make sure your child’s vitamin D levels are checked, as low vitamin D appears linked to worse eczema (moderate confidence). Continue using basic eczema care like moisturizing regularly, even while on dupilumab (high confidence).
This research is most relevant for children with moderate-to-severe eczema and their parents. It’s also important for pediatricians and dermatologists who treat children. If your child has mild eczema controlled with basic moisturizers and topical creams, this research is less directly applicable, though the severity scoring system could still help your doctor assess your child’s condition. Adults with eczema should note that while dupilumab works in adults too, this study specifically looked at children.
Most children showed noticeable improvement by week 4 of dupilumab treatment. Significant improvement (50% or better) typically occurred by week 12. The best results (near-complete clearing) took the full 16 weeks. Individual timelines vary, so talk to your doctor about realistic expectations for your child.
Frequently Asked Questions
How can doctors tell if my child’s eczema is severe?
Doctors now use a simple 0-9 point scoring system that checks five signs: when eczema started, how dry the skin is, specific skin patterns, vitamin D levels, and white blood cell counts. This system correctly identifies severe cases 88.5% of the time, making diagnosis faster and more accurate.
Does dupilumab actually work for kids with bad eczema?
Research shows dupilumab works very well in children. Within 16 weeks, 86.52% of children showed at least 50% improvement, 65% showed 75% improvement, and 34% had nearly complete clearing. Most children saw benefits starting by week 4.
What are the side effects of dupilumab in children?
According to a 2026 study of 236 children, adverse events from dupilumab were mild and infrequent. Most children tolerated the medicine well, making it a safe option for treating moderate-to-severe eczema in kids.
Can low vitamin D make my child’s eczema worse?
Research shows low vitamin D is one of five key signs associated with severe eczema in children. While vitamin D deficiency alone doesn’t cause eczema, it appears linked to worse severity, so checking and maintaining adequate vitamin D levels may help.
How long does it take to see improvement with dupilumab treatment?
Most children start seeing noticeable improvement by week 4 of dupilumab treatment. Significant improvement (50% or better) typically occurs by week 12, with the best results (near-complete clearing) taking the full 16 weeks of treatment.
Want to Apply This Research?
- Track your child’s eczema severity weekly using the five key indicators: skin dryness (rate 1-10), presence of bumpy skin texture (yes/no), any new rashes or flare-ups (yes/no), and note any mood or sleep changes related to itching. This creates a simple home monitoring system that mirrors the clinical scoring system.
- Set weekly reminders to apply moisturizer twice daily and take vitamin D supplements if recommended by your doctor. Log these habits in the app to track adherence and correlate with skin improvement. Also track any side effects or concerns to discuss with your doctor at appointments.
- Create a weekly photo log of affected skin areas (same location, same lighting) to visually track improvement over 4, 12, and 16 weeks. Pair this with weekly symptom scores (itching intensity, sleep disruption, visible redness) to build a comprehensive picture of treatment response. Share this data with your doctor to optimize treatment decisions.
This article summarizes research findings and is not a substitute for professional medical advice. Atopic dermatitis is a complex condition that requires individualized assessment and treatment by a qualified healthcare provider. Do not start, stop, or change any eczema treatments, including dupilumab, without consulting your child’s pediatrician or dermatologist. While this research shows dupilumab is effective and safe in children, it may not be appropriate for every child. Your doctor will consider your child’s specific medical history, other medications, and individual circumstances when recommending treatment. If your child experiences any concerning side effects, contact your healthcare provider immediately.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.